ACEN (OTC:ACPIF) Stock, Quote.Headers.trade-ideas

ACEN Corp is a Philippines-based energy provider. The company is mainly involved in the business of Renewables and Thermal energy. It also holds interests in the business of oil and gas exploration and production. The company operates in three segments: The Philippines segment, the International segment, and the Parent and Others segment The Philippines segment, which accounts for the vast majority of its revenue, is into Retail Electricity Supply, Renewables - generation, transmission, distribution, and supply of electricity using renewable sources, Thermal - generation, transmission, distribution, and supply of electricity using the conventional way of energy generation, Project development, Leasing, bulk water supply, and Petroleum and exploration.

ACEN Corp

WIIM

PHIN

Phinia shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.

<p><a href="https://fb.watch/uP-5gobUA-/" title="https://fb.watch/uP-5gobUA-/">https://fb.watch/uP-5gobUA-/</a></p>


News

Events

LIVE: Watch Meta Connect 2024 Event, To Begin Shortly

<p>Guggenheim  analyst Steven Forbes   maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Buy and raises the price target from $3225 to $3350.</p>


Price Target

Analyst Ratings

Guggenheim Maintains Buy on AutoZone, Raises Price Target to $3350

Macro Economic Events

Econ #s

Economics

U.S. Sells $70B In 5-Year Notes At 3.519% High Yield Vs 3.645% Prior

<p>Guggenheim  analyst Michael Morris   maintains Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) with a Buy and lowers the price target from $19 to $14.</p>


PARA

Guggenheim Maintains Buy on Paramount Global, Lowers Price Target to $14

<p>Payments company <strong>Visa Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) was hit with an antitrust lawsuit by the U.S. Department of Justice (DOJ) Tuesday that analysts say could take years to sort out and will likely hurt shares<a href="https://www.benzinga.com/news/24/09/41009461/visa-shares-are-moving-lower-today-what-you-need-to-know"> in the short term.</a></p>
<p><br /><strong>What Happened:</strong> The DOJ alleged Visa<a href="https://www.benzinga.com/markets/equities/24/09/40996656/visa-reportedly-faces-doj-antitrust-lawsuit-alleging-monopolization-of-us-debit-card-market-amid"> used anticompetitive practices</a> in the debit network market in a lawsuit filed in U.S. District Court in New York on Tuesday.</p>
<p>Visa controls over 60% of the U.S. debit transactions market, according to the lawsuit. The lawsuit alleged Visa illegally operates a monopoly by using exclusionary agreements with banks and merchants to prevent competition in the market.</p>
<p>"We allege that Visa has unlawfully amassed the power to extract fees that far exceed what it could charge in a competitive market," Attorney General <strong>Merrick B. Garland</strong> said.</p>
<p>Garland said merchants and banks pass these costs on to consumers.</p>
<p>"As a result, Visa's unlawful conduct affects not just the price of one thing — but the price of nearly everything."</p>
<p>The DOJ said it is seeking to "restore competition" to the market.</p>
<p>As Visa stock falls, analysts are weighing in with short-term and long-term repercussions for the company.</p>
<p><strong>Goldman Sachs on Visa</strong>: Anti-competitive allegations against Visa were "broader in scope" than reported allegations from the Department of Justice were expected to be, Goldman Sachs analyst <strong>Will Nance</strong> said in a new investor note.</p>
<p>The analyst said the lawsuit accused Visa of using incentive pricing, limiting the ability of alternative networks, threatening to terminate partnerships and entering into agreements with financial incentives to partners.</p>
<p>"The DOJ alleges that through these practices, Visa has abused its monopolistic power to maintain high fees on debit transactions, and limit competition and innovation in debt markets," Nance said.</p>
<p>The analyst has a Buy rating on Visa with a $317 price target.</p>
<p>The DOJ is seeking to restore a competitive market to the space, the analyst added.</p>
<p>"We believe this litigation is likely to be an overhang for near-term performance, particularly as the scope of the lawsuit is broader than we expected."</p>
<p>The analyst said the financial implications could be a 1.8% impact on earnings per share for every 5% loss in U.S. debit market share.</p>
<p><strong>Read Also:<a href="https://www.benzinga.com/government/24/09/40979995/consumers-turn-to-401-k-s-to-pay-down-credit-cards-life-is-expensive"> Consumers Turn To 401(k)s To Pay Down Credit Cards: &#8216;Life Is Expensive&#8217;</a></strong></p>
<p><strong>JPMorgan on Visa</strong>: The DOJ antitrust lawsuit against Visa could take years to be completed, and will likely hurt the stock in the near-term, JPMorgan analyst <strong>Tien-tsin Huang</strong> said.</p>
<p>"The DOJ is arguing that Visa's contracts and pricing structure prevent other networks (including Mastercard, FI's STAR/Accel, FIS's NYCE, etc.) as well as ‘fintech debit networks' (Apple, Block and PayPal) from competing on a level playing field," Huang said.</p>
<p>The analyst said the lawsuit is complicated but the items covered aren't too surprising as they are common practices in the payments sector.</p>
<p>"We suspect a resolution here will be multiple years in the making given historical precedent but wouldn't be surprised to see some ongoing weight on Visa's shares near-term given, on the margin, regulatory attention likely pressure pricing power."</p>
<p>The analyst has an Overweight rating on Visa with a $320 price target.</p>
<p>Huang said the lawsuit could provide overhang benefits to <strong>Mastercard Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>),<strong> Fiserv Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) and <strong>Fidelity National Information Services</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>).</p>
<p>"We reiterate our preference for top-pick Mastercard, but note that Vis has effectively navigated various regulatory headwinds both domestically and overseas."</p>
<p>The analyst said Fiserve and Fidelity National Information Services could benefit from measures taken in the debit market, while Mastercard could benefit given its lower market share in debit (25% vs. Visa's 60%) and actions taken to make the two companies more competitive.</p>
<p>"Visa being the largest domestic payment company, sitting at the center of transactions between multiple parties means it must delicately balance these dynamics while not overreaching competitively – a challenging task, and it falls to the court to decide what side of the line Visa falls on in this case."</p>
<p><br /><strong>V Price Action: </strong>Visa stock is down 1.31% to $269.22 on Wednesday versus a 52-week trading range of $227.78 to $293.07. Visa stock is up 13% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/exclusives/24/09/40962321/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Fintech news covering the emerging Financial Technology services sector

Fintech

Government

Reiteration

Legal

Trading Ideas

Visa Stock Has Near-Term 'Overhang' From DOJ Antitrust Lawsuit: Analyst Picks 3 Stocks To Benefit

<p>Guggenheim  analyst Raymond McDonough   maintains Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) with a Buy and raises the price target from $64 to $70.</p>


PRGS

Guggenheim Maintains Buy on Progress Software, Raises Price Target to $70

<p>Across the recent three months, 10 analysts have shared their insights on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $66.3, a high estimate of $80.00, and a low estimate of $37.00. Witnessing a positive shift, the current average has risen by 0.3% from the previous average price target of $66.10.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283684_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive Celldex Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andy Chen</td>
<td>Wolfe Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celldex Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Celldex Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Celldex Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Celldex Therapeutics analyst ratings.</strong></a></p>
<h2>About Celldex Therapeutics</h2>
<p>Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.</p>
<h3>Financial Milestones: Celldex Therapeutics's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Celldex Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>832.09%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-1434.83%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Celldex Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-4.34%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Celldex Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-4.18%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.0</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CLDX

A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics

<p>Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $105.12, a high estimate of $113.00, and a low estimate of $100.00. Witnessing a positive shift, the current average has risen by 2.63% from the previous average price target of $102.43.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283667_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Encompass Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$100.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Encompass Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Encompass Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Encompass Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Encompass Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EHC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Encompass Health analyst ratings.</strong></a></p>
<h2>Get to Know Encompass Health Better</h2>
<p>Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.</p>
<h3>Encompass Health: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Encompass Health displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>9.61%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Encompass Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>8.71%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Encompass Health's ROE excels beyond industry benchmarks, reaching <strong>6.33%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.8%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Encompass Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.6</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Encompass Health Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

CIFR

Cipher Mining shares are trading higher after Northland Capital Markets initiated coverage on the stock with an Outperform rating and announced a $6 price target.

REGN

CNBC Halftime Report Final Trades: Trane Technologies, American Tower, Regeneron Pharmaceuticals, Taiwan Semiconductor Manufacturing

<p>Financial giants have made a conspicuous bullish move on Unity Software. Our analysis of options history for Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) revealed 24 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $73,625, and 22 were calls, valued at $2,431,788.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $60.0 for Unity Software over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Unity Software's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Unity Software's significant trades, within a strike price range of $20.0 to $60.0, over the past month.</p>
<h3>Unity Software Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283660_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$3.55</td>
<td>$3.2</td>
<td>$3.4</td>
<td>$20.00</td>
<td>$1.7M</td>
<td>13.5K</td>
<td>5.2K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$23.00</td>
<td>$55.8K</td>
<td>3.5K</td>
<td>254</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.3</td>
<td>$5.25</td>
<td>$5.25</td>
<td>$20.00</td>
<td>$54.6K</td>
<td>20.0K</td>
<td>5.5K</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$2.88</td>
<td>$2.79</td>
<td>$2.88</td>
<td>$23.00</td>
<td>$53.2K</td>
<td>5.2K</td>
<td>900</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$2.66</td>
<td>$2.56</td>
<td>$2.61</td>
<td>$23.00</td>
<td>$48.2K</td>
<td>5.2K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Unity Software</h3>
<p>Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.</p>
<p>In light of the recent options history for Unity Software, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Unity Software's Current Market Status</h3>
<ul>
<li>With a trading volume of 9,822,277, the price of U is down by -2.7%, reaching $22.57.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 43 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Unity Software with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Behind the Scenes of Unity Software's Latest Options Trends

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>IBM</strong>.</p>
<p>Looking at options history for IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) we detected 17 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 52% of the investors opened trades with bullish expectations and 11% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $140,473 and 14, calls, for a total amount of $770,416.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $175.0 to $240.0 for IBM over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of IBM stands at 1456.17, with a total volume reaching 1,828.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in IBM, situated within the strike price corridor from $175.0 to $240.0, throughout the last 30 days.</p>
<h3>IBM Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283655_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$24.4</td>
<td>$24.25</td>
<td>$24.4</td>
<td>$200.00</td>
<td>$197.6K</td>
<td>10</td>
<td style="text-align: right;">201</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/25/24</td>
<td>$8.75</td>
<td>$8.3</td>
<td>$8.53</td>
<td>$220.00</td>
<td>$83.6K</td>
<td>551</td>
<td style="text-align: right;">282</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$39.15</td>
<td>$38.25</td>
<td>$38.72</td>
<td>$190.00</td>
<td>$62.1K</td>
<td>594</td>
<td style="text-align: right;">16</td>
</tr>
<tr>
<td>IBM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.3</td>
<td>$15.1</td>
<td>$15.21</td>
<td>$230.00</td>
<td>$61.3K</td>
<td>15</td>
<td style="text-align: right;">149</td>
</tr>
<tr>
<td>IBM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.3</td>
<td>$8.25</td>
<td>$8.3</td>
<td>$240.00</td>
<td>$53.9K</td>
<td>2.5K</td>
<td style="text-align: right;">71</td>
</tr>
</tbody>
</table>
</p>
<h3>About IBM</h3>
<p>IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 350,000 people. The company has a robust roster of 80,000 business partners to service 5,200 clients, which includes 95% of all Fortune 500. While IBM is a B2B company, IBM's outward impact is substantial. For example, IBM manages 90% of all credit card transactions globally and is responsible for 50% of all wireless connections in the world.</p>
<p>Having examined the options trading patterns of IBM, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>IBM's Current Market Status</h3>
<ul>
<li>With a trading volume of 869,227, the price of IBM is up by 0.02%, reaching $221.01.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 28 days from now.</li>
</ul>
<h3>What Analysts Are Saying About IBM</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $192.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from UBS has decided to maintain their Sell rating on IBM, which currently sits at a price target of $145.<br />
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on IBM, maintaining a target price of $240. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest IBM options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With IBM

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Colgate-Palmolive</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CL, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for <strong>Colgate-Palmolive</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 90% bullish and 10%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $32,560, and 9, calls, for a total amount of $794,180.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $97.5 to $110.0 for Colgate-Palmolive over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Colgate-Palmolive's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Colgate-Palmolive's significant trades, within a strike price range of $97.5 to $110.0, over the past month.</p>
<h3>Colgate-Palmolive Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283650_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$99.00</td>
<td>$110.0K</td>
<td style="text-align: right;">1</td>
<td>1.4K</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.5</td>
<td>$5.2</td>
<td>$5.5</td>
<td>$99.00</td>
<td>$110.0K</td>
<td style="text-align: right;">1</td>
<td>1.0K</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$99.00</td>
<td>$109.8K</td>
<td style="text-align: right;">1</td>
<td>1.6K</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$99.00</td>
<td>$109.8K</td>
<td style="text-align: right;">1</td>
<td>1.2K</td>
</tr>
<tr>
<td>CL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.4</td>
<td>$99.00</td>
<td>$107.8K</td>
<td style="text-align: right;">1</td>
<td>600</td>
</tr>
</tbody>
</table>
</p>
<h3>About Colgate-Palmolive</h3>
<p>Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.</p>
<p>In light of the recent options history for Colgate-Palmolive, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Colgate-Palmolive's Current Market Status</h3>
<ul>
<li>Trading volume stands at 845,127, with CL's price down by -0.07%, positioned at $103.72.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 30 days.</li>
</ul>
<h3>Expert Opinions on Colgate-Palmolive</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $113.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from Wells Fargo lowers its rating to Underweight with a new price target of $100.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Colgate-Palmolive, which currently sits at a price target of $122.<br />
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $121.<br />
&#x2A; Reflecting concerns, an analyst from Deutsche Bank lowers its rating to Hold with a new price target of $109.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Colgate-Palmolive with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Check Out What Whales Are Doing With Colgate-Palmolive

<p>Across the recent three months, 12 analysts have shared their insights on CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $29.58, a high estimate of $32.00, and a low estimate of $28.00. Experiencing a 4.02% decline, the current average is now lower than the previous average price target of $30.82. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283643_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of CenterPoint Energy by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Arcaro</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ross Fowler</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Andrew Weisel</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Sarah Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Jeremy Tonet</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$28.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Sophie Karp</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CenterPoint Energy. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CenterPoint Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of CenterPoint Energy's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of CenterPoint Energy's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CNP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on CenterPoint Energy analyst ratings.</strong></a></p>
<h2>Discovering CenterPoint Energy: A Closer Look</h2>
<p>CenterPoint Energy owns a portfolio of businesses. Its regulated electric utilities provide transmission and distribution services to more than 2.5 million customers in the Houston area, southern Indiana, and west central Ohio. The company has natural gas distribution systems serving approximately 4 million customers.</p>
<h3>CenterPoint Energy: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, CenterPoint Energy showcased positive performance, achieving a revenue growth rate of <strong>1.6%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Utilities sector.</p>
<p><strong>Net Margin:</strong> CenterPoint Energy's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>11.97%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CenterPoint Energy's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.24%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.56%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> CenterPoint Energy's debt-to-equity ratio is below the industry average. With a ratio of <b>1.85</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying CenterPoint Energy: Insights From 12 Analyst Reviews

<p>Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) in the last three months.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $12.8, a high estimate of $16.00, and a low estimate of $11.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.54%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283636_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Repay Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Repay Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Repay Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Repay Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RPAY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Repay Holdings analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Repay Holdings</h2>
<p>Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segment, Consumer Payment and Business Payments.</p>
<h3>Financial Insights: Repay Holdings</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Repay Holdings's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>4.35%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-5.43%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Repay Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.5%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Repay Holdings's ROA excels beyond industry benchmarks, reaching <strong>-0.27%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.54</strong>, Repay Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RPAY

A Closer Look at 5 Analyst Recommendations For Repay Holdings

<p>Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) has outperformed the market over the past 15 years by 11.9% on an annualized basis producing an average annual return of 23.93%. Currently, Ulta Beauty has a market capitalization of $18.88 billion. </p>
<p><strong>Buying $100 In ULTA:</strong> If an investor had bought $100 of ULTA stock 15 years ago, it would be worth <strong>$2,426.86</strong> today based on a price of $400.68 for ULTA at the time of writing.</p>
<h3>Ulta Beauty's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283628_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ULTA

If You Invested $100 In This Stock 15 Years Ago, You Would Have $2,400 Today

<p>Insight Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSIT#NASDAQ">NSIT</a>) has outperformed the market over the past 20 years by 4.68% on an annualized basis producing an average annual return of 13.07%. Currently, Insight Enterprises has a market capitalization of $6.91 billion. </p>
<p><strong>Buying $100 In NSIT:</strong> If an investor had bought $100 of NSIT stock 20 years ago, it would be worth <strong>$1,174.12</strong> today based on a price of $211.99 for NSIT at the time of writing.</p>
<h3>Insight Enterprises's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283624_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NSIT

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today

<p>Guggenheim  analyst Gregory Francfort   maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Buy and raises the price target from $190 to $195.</p>


TXRH

Guggenheim Maintains Buy on Texas Roadhouse, Raises Price Target to $195

<p>Ratings for bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $3.8, a high estimate of $6.00, and a low estimate of $2.00. A decline of 26.92% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727283614_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of bluebird bio by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$4.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jack Allen</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to bluebird bio. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of bluebird bio compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of bluebird bio's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into bluebird bio's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BLUE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on bluebird bio analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know bluebird bio Better</h2>
<p>bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.</p>
<h3>Financial Milestones: bluebird bio's Journey</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining bluebird bio's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>680.05%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-375.84%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> bluebird bio's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-42.88%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> bluebird bio's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-11.16%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> bluebird bio's debt-to-equity ratio surpasses industry norms, standing at <strong>3.16</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

ACEN

ACEN (ACPIF) Forecast

ACEN (OTC:ACPIF) Stock, Quote.Headers.trade-ideas